Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict who will relapse after brain inflammation?

NCT ID NCT07722286

Knowledge-focused Sponsor: Shen Chun-Hong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study examines a rare brain disease called anti-LGI1 encephalitis, where the immune system attacks a protein in the brain, causing memory loss, confusion, and seizures. Researchers will review medical records from 112 patients across five hospitals in Eastern China to see how often the disease returns or causes lasting problems. The goal is to identify factors that raise the risk of relapse or poor recovery, which could lead to better long-term care strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors identify which patients need closer monitoring and longer treatment to prevent relapses and improve long-term quality of life.
What could go wrong
This is an observational study looking back at medical records, so it cannot prove cause and effect. Results may not apply to all patients with this rare condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

112 people

The number who actually took part.

Started

Jan 2015

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients at five tertiary medical centers from four cities in Eastern China (Second Affiliated Hospital of Zhejiang University School of Medicine, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Shaoxing People's Hospital, Ningbo Medical Center Lihuili Hospital, and Huzhou Third People's Hospital)

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Characteristic presentations of anti-LGI1 encephalitis; 2. LGI1-immunoglobulin G (IgG) positivity in serum and/or cerebrospinal fluid (CSF) by fixed cell-based assay (Euroimmun, Lübeck, Germany) 3. follow-up ≥ 18 months after initial immunotherapies 4. exclusion of alternative diagnoses Exclusion Criteria: 1. presence of coexisting neural autoantibodies 2. history of central nervous system (CNS) infections, severe neurological or primary psychiatric disorders 3. no prior use or lack of first-line immunotherapy 4. insufficient follow-up data

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune encephalitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system autoimmune encephalitis limbic encephalitis limbic encephalitis with LGI1 antibodies Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune encephalitis LGI1 encephalitis Limbic encephalitis

Contacts and locations

Locations

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.